The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis.
BACKGROUND
Emerging evidence suggests that ataxia telangiectasia-mutated (ATM) is involved in numerous damage repair signaling pathways and cell-cycle checkpoints. Heterozygous carriers of ATM-mutations have an increased risk for the development of breast cancer. The purpose of this study is to evaluate the association between ATM exon39 5557G > A (D1853N, rs1801516) polymorphism and breast cancer susceptibility with the use of a meta-analysis.


METHODS
By searching PubMed and Embase databases, a total of 9 epidemiological studies with 4,191 cases and 3,780 controls were identified. Crude odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) for ATM D1853N polymorphism and breast cancer risk were calculated using fixed- or random-effects model based on the degree of heterogeneity among studies.


RESULTS
No significant association between the ATM D1853N polymorphism and breast cancer risk was observed in overall analysis (GA versus GG: OR = 1.18; 95% CI, 0.90-1.53; AA versus GG: OR = 0.77; 95% CI, 0.58-1.03; dominant model: OR = 1.16; 95% CI, 0.89-1.51; and recessive model: OR = 0.78; 95% CI, 0.59-1.04, respectively).


CONCLUSIONS
Our results indicate that ATM D1853N polymorphism is not a risk factor for developing breast cancer.
Gao
Lin-Bo
LB
Laboratory of Molecular Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Pan
Xin-Min
XM
Sun
Hong
H
Wang
Xia
X
Rao
Li
L
Li
Li-Juan
LJ
Liang
Wei-Bo
WB
Lv
Mei-Li
ML
Yang
Wen-Zhong
WZ
Zhang
Lin
L
D064007:Ataxia Telangiectasia Mutated Proteins; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D018797:Cell Cycle Proteins / Q000235:genetics*; D004268:DNA-Binding Proteins / Q000235:genetics*; D005091:Exons; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D018570:Risk Assessment; D012307:Risk Factors; D025521:Tumor Suppressor Proteins / Q000235:genetics*
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases
Stat Med. 2002 Jun 15;21(11):1539-58
12111919
Int J Radiat Biol. 1994 Dec;66(6 Suppl):S177-82
7836845
Nat Genet. 2006 Aug;38(8):873-5
16832357
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):883-7
15279773
Cancer Res. 1994 Sep 1;54(17):4586-9
8062246
BMJ. 1997 Sep 13;315(7109):629-34
9310563
Am J Hum Genet. 2000 Feb;66(2):494-500
10677309
BMC Cancer. 2008 Apr 23;8:117
18433505
Genes Chromosomes Cancer. 1999 Jul;25(3):212-21
10379867
Med Oncol. 2011 Sep;28(3):733-7
20396981
Cancer Genet Cytogenet. 1996 Dec;92(2):130-4
8976369
J Natl Cancer Inst. 1959 Apr;22(4):719-48
13655060
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
Br J Cancer. 1999 Mar;79(7-8):1304-7
10098776
Breast Cancer Res Treat. 2011 Feb;125(3):827-35
20640595
Science. 1995 Jun 23;268(5218):1749-53
7792600
Nat Genet. 2007 Mar;39(3):352-8
17293864
Breast Cancer Res Treat. 2008 Jan;107(2):281-8
17351744
Cancer Res. 2001 Oct 15;61(20):7608-15
11606401
N Engl J Med. 1987 May 21;316(21):1289-94
3574400
N Engl J Med. 1991 Dec 26;325(26):1831-6
1961222
Mutat Res. 2000 Apr;462(2-3):167-78
10767628
Cancer Res. 1995 Jul 15;55(14):3003-7
7606718
Cancer. 2004 Apr 1;100(7):1345-51
15042666
Adv Cancer Res. 2001;83:209-54
11665719
Eur J Cancer. 2010 May;46(8):1333-43
20400292
Cancer Res. 1994 Dec 1;54(23):6270-4
7954477
Breast Cancer Res Treat. 2008 Jan;107(2):243-8
17393301
Genome Med. 2009 Jan 22;1(1):12
19348699
Breast Cancer Res Treat. 2011 Jan;125(2):571-4
20640596
Cancer Res. 1998 Apr 1;58(7):1376-9
9537233
BMC Cancer. 2006 Aug 16;6:209
16914028
Genes Chromosomes Cancer. 1990 Nov;2(4):339-40
2268581
Cancer Res. 2003 Dec 15;63(24):8717-25
14695186
J Cancer Res Clin Oncol. 2008 Aug;134(8):873-82
18264724
Int J Cancer. 2005 Aug 10;116(1):69-72
15756685